Related Experiment Videos

Prospective, longitudinal oncology registries enabling advanced real-world evidence: the iOMEDICO experience

M Jänicke1, S Dille2, M Frank3

  • 1Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg, Germany.

ESMO Real World Data and Digital Oncology
|August 22, 2026
PubMed
Abstract

Insights

High-quality cancer registries offer valuable real-world data to complement randomized controlled trials (RCTs). These prospective, longitudinal oncology registries capture comprehensive patient information, enhancing treatment research and providing realistic outcome expectations for diverse patient populations.

Area of Science:

  • Oncology
  • Real-World Evidence
  • Clinical Research

Background:

  • Randomized controlled trials (RCTs) are limited by strict eligibility criteria, rare head-to-head comparisons, and differing real-world effectiveness.
  • High-quality cancer registries capture treatment reality and effectiveness outside trial settings.
  • Prospective, longitudinal oncology registry data offer advanced research capabilities complementing RCTs.

Purpose of the Study:

  • To describe how prospective, longitudinal oncology registry data can be leveraged for advanced research.
  • To highlight the capabilities of the iOMEDICO registry network in Germany.
  • To demonstrate the value of real-world data in complementing RCTs.

Main Methods:

  • Operation of nine prospective, multicenter registry platforms across major cancer types in Germany by the iOMEDICO network.
  • Use of regulatory-grade electronic data capture with audit trails and continuous data management.
  • Systematic collection of demographics, clinical variables, comorbidities, biomarkers, treatment pathways, and patient-reported outcomes (PROs).

Main Results:

  • Documentation of over 55,000 patients across more than 400 diverse care sites.
  • Registry data enable patient-centered research, including population characterization, predictive modeling, and comparative effectiveness research.
  • Applications include evaluating standards of care, identifying unmet needs, translational research, and PRO evaluation.

Conclusions:

  • Well-designed prospective, longitudinal registries provide broad and deep real-world data.
  • These registries complement RCTs, inform Health Technology Assessments, and fill knowledge gaps.
  • They enhance treatment transparency, address evidence gaps, and set realistic outcome expectations for heterogeneous patient populations.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Longitudinal Research02:20

Longitudinal Research

Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...